SPY330.77-3.73 -1.12%
DIA276.49-2.41 -0.87%
IXIC10,793.28-117.00 -1.07%

Morgan Stanley Maintains Overweight on Regenxbio, Raises Price Target to $56

Morgan Stanley maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $55 to $56.

Benzinga · 05/11/2020 13:34

Morgan Stanley maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $55 to $56.